Published in Cancer Metastasis Rev on March 01, 2011
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol (2013) 2.00
The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell (2012) 1.98
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology (2012) 1.43
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Killing a cancer: what are the alternatives? Nat Rev Cancer (2012) 1.30
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
Calreticulin in the immune system: ins and outs. Trends Immunol (2012) 1.23
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Two modes of cell death caused by exposure to nanosecond pulsed electric field. PLoS One (2013) 1.06
The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 1.04
Immunogenic cell death in radiation therapy. Oncoimmunology (2013) 1.04
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res (2014) 1.01
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene (2014) 0.97
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Short Term Hypoxia Synergizes with Interleukin 15 Priming in Driving Glycolytic Gene Transcription and Supports Human Natural Killer Cell Activities. J Biol Chem (2016) 0.96
Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol (2014) 0.95
Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res (2014) 0.95
Activation of dendritic cells by tumor cell death. Oncoimmunology (2012) 0.94
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res (2014) 0.90
Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells. PLoS One (2014) 0.90
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother (2013) 0.87
Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87
Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia. Cell Stress Chaperones (2014) 0.87
Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones (2013) 0.85
Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions. Oncoscience (2014) 0.84
Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. Transl Oncol (2016) 0.84
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm (2012) 0.83
Nanomaterials and autophagy: new insights in cancer treatment. Cancers (Basel) (2013) 0.83
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82
The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy. Front Immunol (2014) 0.82
Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther (2016) 0.80
Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell (2014) 0.80
Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression. PLoS One (2011) 0.80
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Sci Rep (2016) 0.79
When Cells Suffocate: Autophagy in Cancer and Immune Cells under Low Oxygen. Int J Cell Biol (2011) 0.79
Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia (2012) 0.79
Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene (2016) 0.79
Editorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality. Front Immunol (2016) 0.78
The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma. PLoS One (2016) 0.78
Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines. Biomed Res Int (2014) 0.78
Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. Oncoimmunology (2013) 0.78
A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma. Q Rev Biophys (2015) 0.77
Attenuated mutant strain of Salmonella Typhimurium lacking the ZnuABC transporter contrasts tumor growth promoting anti-cancer immune response. Oncotarget (2015) 0.76
Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. Oncoimmunology (2017) 0.75
Immunomodulatory Response Triggered by the Alkaloids, 3-Amino-7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (ABQ-48) and 3-Nitro-7-Benzylbenzimidazo [3,2-a] Quinolinium Chloride (NBQ-48). J Cancer Res Ther Oncol (2015) 0.75
Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol (2017) 0.75
Immunotherapy in genitourinary malignancies. Curr Opin Urol (2016) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47
The hallmarks of aging. Cell (2013) 14.29
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The pathophysiology of mitochondrial cell death. Science (2004) 13.87
Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72
Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
Autophagy and aging. Cell (2011) 5.96
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Does autophagy contribute to cell death? Autophagy (2005) 3.21
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61
Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56